A new research partnership aims to enhance the design of the delivery model for the investigational COMP360 psilocybin treatment. However, any breakthrough would be contingent on FDA approval.
COMPASS Pathways plc (Nasdaq: CMPS), a pioneering biotechnology company dedicated to advancing patient access to evidence-based innovation in mental health, and Hackensack Meridian Health (HMH), a leading not-for-profit healthcare organization in New Jersey, recently announced the collaboration.
In a joint effort to address real-world challenges associated with mental health conditions, COMPASS and HMH will work together to improve health outcomes and enhance patient and provider experiences. The focus will be treatment-resistant depression. In addition, collaboration will play a crucial role in informing the design of future clinical trials for COMP360 psilocybin treatment and providing valuable insights into its potential delivery to patients.
COMP360, COMPASS’ proprietary formulation of synthetic psilocybin, is administered alongside psychological support. Hackensack Meridian Health, with its extensive network of 18 hospitals and over 500 patient care locations, offers a comprehensive range of medical services. The company focuses on innovative research and life-enhancing care. Notably, the network boasts the only number one ranked adult and children’s hospitals in New Jersey, according to the U.S. News & World Report for 2023-24.
Read more: Afghanistan Veteran gets Health Canada approval for psilocybin treatment from Apex Labs
Read more: PharmAla Biotech ships first batch of MDMA and psilocybin to be used as medicines in Australia
Collaboration is key
Robert C. Garrett, CEO of Hackensack Meridian Health, expressed pride in collaborating with COMPASS Pathways. He highlighted the significance of addressing challenging mental health conditions. The collaboration leverages HMH’s leadership in mental health and extensive experience in treating depression in clinical practice. The goal is to ultimately shape the accessibility of new mental health treatments for patients.
Kabir Nath, CEO of COMPASS Pathways, emphasized the importance of the collaboration in understanding how COMP360 psilocybin treatment, if approved, could be effectively delivered to patients. He sees this partnership with HMH, one of the largest and most integrated healthcare networks in the U.S., as a significant milestone in COMPASS’ mission to offer improved treatment options for individuals in urgent need.
The collaboration holds promise for advancing the field of mental health research and providing innovative solutions for patients grappling with treatment-resistant depression. The results of their collaborative efforts could potentially pave the way for groundbreaking advancements in psilocybin-based therapies.
zartasha@mugglehead.com
